Eclipsebio has acquired Terrain Bio to accelerate an integrated platform for RNA therapeutic design, manufacturing and validation. The deal combines Terrain’s machine‑learning RNA analytics with Eclipsebio’s sequencing‑first validation capability to create an end‑to‑end offering for RNA drug developers. Eclipsebio said the acquisition will let customers iteratively design RNA constructs, measure structure and translation at high resolution, and translate insights into manufacturing robustness and quality‑by‑design. CEO Peter Chu described the move as advancing Eclipsebio’s goal of supporting RNA developers earlier in the pipeline while keeping deep sequencing validation at the center of decision‑making. The transaction illustrates continued consolidation in the RNA tools and services market as developers seek turnkey solutions that compress design cycles and improve manufacturability for clinical candidates.